Exclusive: Unike Biotech Completes Tens of Millions of RMB in Angel Financing; Riemann Hypothesis Serves as Exclusive Financial Advisor for This Round
UNIKE BIOPHARMACEUTICALS
Innovative Protein and Peptide Drug Developer
Riemann-Hypothesis
Boutique Investment Bank in the Biomedical Field
Longhope Capital
Professional Investment Institutions
Founder Financing Review
Reviewing the Fundraising Journey of This Round, Dr. Zou Peijian, Founder of Unike, stated: “Throughout this round of financing, Riemann Hypothesis consistently demonstrated enthusiasm and resilience, continuously overcoming key bottlenecks in the transaction process, and ultimately facilitating the smooth closure of the financing. This achievement is closely attributed to Riemann Hypothesis’s conscientiousness, sense of responsibility, and deep involvement, as well as its seamless collaboration with all parties involved.”
Riemann Hypothesis involves a level of specialized expertise, strong sense of Responsibility and the indomitable spirit, which are rare in the industry and throughout every stage of this round of financing. Meanwhile, leveraging its profound understanding of project financing, particularly the most challenging early-stage funding, Riemann Hypothesis continuously refined its financing strategy, overcame numerous obstacles, and ultimately ensured the successful closure of the financing round.
Most importantly, we highly appreciate the exclusive strategic partnership and fully managed cooperation model established between both parties. This arrangement has not only saved substantial trial-and-error costs in financing but also freed up significant resources, allowing us to focus on research and development. We are deeply grateful for this support and will continue to maintain a long-term strategic collaboration with Riemann Hypothesis.
Recently, Unike (Hangzhou) Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Unike”) completed an angel round of financing amounting to tens of millions of RMB. This round of financing was led by Longhope Capital, Riemann Hypothesis Serves as the Exclusive Financial Advisor for This Round of Financing. This round of funding will be primarily directed toward the research and development, validation, and clinical trial applications of innovative drug pipelines built upon our core technology platform, thereby comprehensively accelerating the R&D progress and industrial commercialization of the company’s long-acting protein and peptide therapeutics.
Unike (Hangzhou) Biopharmaceutical Technology Co., Ltd. was established in Hangzhou’s Binjiang District in April 2026. It is an innovative pharmaceutical company driven by cutting-edge proprietary technologies. The company specializes in the research and development as well as industrial translation of long-acting protein and peptide therapeutics, striving to build a globally leading Source Innovation R&D Platform for Long-Acting Protein and Peptide Drugs.
The company has assembled a world-class R&D team, with its core members hailing from top global research institutions and leading pharmaceutical companies. This team combines cutting-edge scientific research capabilities with proven experience in the industrialization and commercialization of new drugs. The company's core technologies are built upon ZT Long-Acting Protein Peptide Proprietary Technology Platform, This technological achievement was selected as one of Nature’s Top 10 Milestone Articles. After more than two decades of continuous iteration and multiple rounds of pilot-scale amplification and validation, the technology system is comprehensive, the process is mature, and it is capable of large-scale mass production, demonstrating strong originality and substantial technical barriers.
Protein and peptide drugs, with advantages such as precise targeting, high safety, and low side effects, are a core development track for innovative drugs globally. However, there exists the common pain points like Short half-life, poor stability, difficult modification, and low druggability, which causes that nearly 10,000 high-quality peptide candidate molecules worldwide are unable to achieve clinical translation due to limitations of traditional technologies, Unike’s proprietary ZT technology platform, centered on its exclusive ZT carrier, offers prominent advantages including broad applicability, high standardization, short R&D cycles, and low R&D costs.
The ZT technology platform aligns with the most advanced international drug design concepts, achieving breakthrough innovations in key dimensions such as extending drug half-life, preserving biological activity, and designing multi-target molecules. It comprehensively enhances the physicochemical properties and stability of drugs, optimizes manufacturing processes, and significantly improves drug developability. Within the framework of independent intellectual property rights, it facilitates innovative translation, resulting in higher-quality innovative drugs with proprietary intellectual property. Furthermore, the ZT technology platform can overcome drug molecule modifications unattainable by traditional technologies, uncover a vast array of untapped novel candidate targets, and establish highly differentiated technical competitiveness.
The company is positioned as a platform-based innovative pharmaceutical enterprise characterized by high barriers to entry, high efficiency, an asset-light model, and scalability. It has established a multi-dimensional, sustainable commercialization system, with business operations encompassing the commercialization of self-developed pipelines, licensing and transfer of domestic and international pipelines, customized technology development, and global patent licensing services. This integrated approach forms a complete commercial closed loop, fostering a global pharmaceutical industry layout with dual presence in both international and domestic markets.
Leveraging its ZT technology platform, the company has proactively established a portfolio of more than 20 Class I innovative drugs, comprehensively covering high-barrier, high-clinical-value therapeutic areas such as metabolic diseases, oncology, autoimmune disorders, and rare diseases. Its pipeline is robust, well-structured, and demonstrates significant commercialization potential. Currently, Unike has reached cooperation intentions with multiple multinational pharmaceutical companies and leading domestic pharmaceutical enterprises, steadily advancing collaborations in pipeline licensing, customized technology development, and joint R&D, thereby accelerating its industrialization and global commercialization processes.